Fusidic acid is an antistaphylococcal agent widely used in the treatment of osteomyelitis. Hepatotoxicity is a well recognized side effect but renal failure is rare. Severe hypocalcaemia and acute renal failure developed in two diabetic patients treated with oral fusidic acid.
CASE HISTORIES

Case 1
A man aged 53, obese, with type 2 diabetes, peripheral vascular disease, retinopathy and hypertension, developed osteomyelitis of the left distal tibia. Routine biochemical tests were normal. He was treated with intravenous ucloxacillin 1 g four times daily and fusidic acid 500 mg three times daily. After three weeks urea was 4.7 mmol/L (reference range 2.5±8.0), creatinine 80 mmol/L (40±135), bilirubin 37 mmol/L (525) and alkaline phosphatase (ALP) 132 U/L (30±250). Corrected serum calcium was 2.35 mmol/L (2.15±2.6). Intravenous¯ucloxacillin was stopped and fusidic acid was continued orally. Two months after presentation he became jaundiced and was readmitted to hospital. Drug therapy on admission included metformin, orlistat, lisinopril, aspirin, cipro¯oxacin and fusidic acid. Urea was then 21.4 mmol/L, creatinine 346 mmol/L, bilirubin 125 mmol/L, ALP 183 U/L, alanine aminotransferase (AST) 227 U/L (normal <40), gammaglutamyltranspeptidase (GGT) 52 U/L (<55). Corrected serum calcium was 1.68 mmol/L and phosphate 0.98 mmol/L (0.7±1.1). Parathyroid hormone was appropriately raised at 79 ng/L (10±50) and 25 hydroxycholecalciferol was 7.0 mg/L (8±50). Hepatitis A and B serology and blood and urine cultures were negative. Metformin, orlistat and cipro¯oxacin were discontinued and 4 L intravenous¯uids was given over the two days after admission. Biochemical ®ndings further deteriorated over these two daysÐurea 26.6 mmol/L, creatinine 404 mmol/L, corrected calcium 1.52 mmol/L, bilirubin 169 mmol/L. There were no clinical or electrocardiographic (ECG) features of hypocalcaemia and the patient was not acidotic. Fusidic acid was withdrawn while lisinopril and aspirin were continued. There was an immediate improvement in renal and hepatic function. Two days after withdrawal, urea was 18.1 mmol/L, creatinine 226 mmol/L, bilirubin 30 mmol/L and corrected calcium 1.67 mmol/L. The patient was discharged four days after admission without calcium supplements or vitamin D therapy. Over the next month biochemical results gradually returned to normalÐurea 5.7 mmol/L, creatinine 131 mmol/L, corrected calcium 2.38 mmol/L, bilirubin 22 mmol/L. The patient did not require surgery for his osteomyelitis and one year later was well.
Case 2
A woman of 63 with type 1 diabetes, peripheral vascular disease, ischaemic heart disease and retinopathy developed osteomyelitis of the left fourth toe and was given oral fusidic acid 500 mg three times daily. Other medication included aspirin, simvastatin, thyroxine, captopril and frusemide. Before treatment plasma glucose was 5.8 mmol/L, urea 7.2 mmol/L, creatinine 98 mmol/L, bilirubin 18 mmol/L, ALP 162 U/L, AST 30 U/L, GGT 81 U/L and corrected serum calcium 2.51 mmol/L. Thyroid function tests were normal. One month later she attended the casualty department because of chest pain and transient loss of consciousness. She was apyrexial and normotensive. ECG showed evidence of a previous inferior myocardial infarct but no QT prolongation. Plasma sodium was 143 mmol/L (133±148), potassium 3.4 mmol/L (3.4± 5.2), urea 29.6 mmol/L, creatinine 146 mmol/L, bilirubin 92 mmol/L, albumin 34 g/L, AST 72 IU/L, ALP 432 IU/L, phosphate 1.3 mmol/L and corrected serum calcium 1.49 mmol/L. The patient refused admission, treatment and further investigation. Forty-eight hours later she was found dead at home. Post mortem examination was not performed.
COMMENT
Fusidic acid is an effective treatment of staphylococcal infections and is often started parenterally, then changed to the oral route. After oral administration the drug rapidly reaches in¯amed bone and synovial¯uid 1 and is generally well tolerated apart from mild gastrointestinal symptoms 2 . It interferes with bile salt transport and secretion 2 , and hepatotoxicity (characterized by conjugated hyperbilirubinaemia and raised alkaline phosphatase) is common. Liver function tests become normal when the drug is stopped (as in case 2), but may also return to normal despite continued therapy. Jaundice is more frequently observed with intravenous administration than with oral administration 2 . Rare reported adverse drug reactions include thrombophlebitis, granulocytopenia, thrombocytopenia and rash 2 .
In the above case histories we describe the development of hepatic dysfunction, acute renal failure and severe hypocalcaemia during treatment with fusidic acid. The ®rst patient's biochemical results improved as soon as he stopped taking the drug and returned to normal within one month. There are two previous reports of renal failure in association with fusidic acid 3, 4 , but serum calcium levels are not mentioned. In one case 5 severe hypocalcaemia developed after intravenous administration of a high dose of fusidic acid (4 g daily) in a phosphate-citrate buffer that gave a total of 44 mmol (1.67 g) phosphate daily. The authors concluded that this dose of phosphate was suf®cient to cause hypocalcaemia 5 . There are no previous reports of hypocalcaemia following oral administration.
Hypocalcaemia in acute renal failure may be the result of a renal calcium leak. However, impaired 25-hydroxylation of vitamin D secondary to hepatic parenchymal damage is the likely mechanism of hypocalcaemia in case 1. Parathyroid hormone levels were raised, serum phosphate was normal and 25-hydroxycholecalciferol was low, suggesting a hepatic cause for the hypocalcaemia. Cipro¯oxacin may cause renal failure but hypocalcaemia and renal impairment persisted after cipro¯oxacin withdrawal and improved only after discontinuation of fusidic acid. In case 2, derangement of liver function and hypocalcaemia were noted within one month of starting fusidic acid therapy. Further information was not available.
Renal failure is often associated with liver failure 3 . Both our patients had moderately raised liver enzyme and bilirubin levels. Acute tubular necrosis secondary to severe hyperbilirubinaemia (up to 739 mmol/L) after fusidic acid therapy is reported in a patient who required dialysis 3 . At the time of writing the Committee on Safety of Medicines/Medicines Control Agency has received 22 reports of renal failure and 9 reports of hypocalcaemia suspected of being associated with fusidic acid. 5 of the cases of renal failure were fatal (CSM, Personal communication).
Portier 6 , in a clinical trial, continued fusidic acid when patients developed abnormal liver function tests, reducing the dose in those with hyperbilirubinaemia 6 . We suggest, however, that urea, creatinine, electrolytes, serum calcium and liver function tests should be measured before fusidic acid is given and that the drug should be avoided in those with abnormal liver function tests and impaired renal function. In patients who receive long-term fusidic acid therapy, serial monitoring of liver function, renal function and serum calcium should be considered. If abnormalities in liver function or renal function occur, the drug should be stopped. Depression and an increased risk of suicide are well recognized after stroke 1 , and are more frequent than would be expected on the basis of disability alone 2 . Patients with symptomatic severe carotid stenosis or occlusion are also at high risk of depression, even in the absence of cerebral infarction 3, 4 . However, the need to assess such risks in these patients is not mentioned in published guidelines 5±7 .
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CASE HISTORY
A man of 53 was referred to a neurology clinic with episodes of transient loss of vision in the left eye and episodes of clumsiness and weakness in his right arm. These usually lasted only a few seconds and tended to come on with exertion, suggesting low cerebral perfusion. There had been no previous cerebrovascular episodes, but he was a longterm heavy smoker, had had a myocardial infarction 5 years earlier and was on aspirin and was taking a lipid-lowering agent for hypercholesterolaemia. He lived with a partner and had no history of depression, self-harm or other psychiatric illness. However, later reports from family members suggested that he had become uncharacteristically depressed since the onset of his symptoms. Visual acuity in the left eye was 6/18, with evidence of ischaemic retinopathy. No other neurological or cardiovascular abnormality was found. Colour-¯ow doppler ultrasound of the internal carotid arteries showed complete occlusion on the left and 50% stenosis on the right. CT brain scan was normal.
Dipyridamole was added to the treatment and the patient was advised to stop smoking. In view of the carotid occlusion, he was not a candidate for carotid endarterectomy. The plan was to review his progress one month later and to consider anticoagulation or extracranialintracranial bypass surgery if his symptoms persisted. Unfortunately the attacks continued and, although they did not change or increase in severity, he committed suicide by overdose before his next appointment.
Although it is impossible to be certain that this patient's medical condition led to his suicide, there seemed to be no other precipitant. According to relatives, his low mood started at around the same time as his symptoms, about three months before his death, and before any changes were made in his treatment.
COMMENT
In patients with stroke the risk of depression and suicide is high 1, 8, 9 . The reported frequency of depression after stroke ranges from 20% to 65% 9 , and frequencies of suicide are up to 14 times greater than expected 1 .
There is also evidence of an increased risk of depression in patients with symptomatic carotid artery stenosis who have had a transient ischaemic attack (TIA) rather than a stroke 3,4,10 . One study compared the frequency of symptoms of depression in elderly patients with stroke (n=25), symptomatic carotid stenosis with TIA (n=25) or non-vascular disease (n=25). Both the symptomatic carotid stenosis group and the stroke group had a signi®cantly higher frequency of symptoms of depression than the nonvascular disease group, and there was a tendency for depression to occur more frequently in those patients with greater than 80% carotid stenosis 3 . Studies of cognitive impairment in TIA patients have also tended to show an association with severe carotid stenosis 4,8±10 .
The cause of psychological disturbance associated with carotid occlusive disease without stroke is not known. It is likely to be partly related to anxiety associated with symptoms and the worry about the risk of stroke, but it may also be directly related to chronic cerebral hypoperfusion. A case has been reported of a woman aged 72 presenting with severe depression who was found to have greater than 95% stenosis of her left internal carotid artery. Her depression had not responded to medical therapy but it resolved permanently and completely within four days of a left carotid endarterectomy 11 .
Although evidence of a link between carotid disease and depression is mainly anecdotal, our case report illustrates the need to be aware of the possibility of depression and the risk of suicide in patients with symptomatic severe carotid 
